基因风险分析揭示了改变的甘氨基转移酶表达作为神经母细胞瘤患者结果的预测因素
Isabelle Ariane Bley1,2, Stefan Behrens1, Michael Spohn1,3
1Research Institute Children's Cancer Center Hamburg, 20251 Hamburg, Germany.
Journal of clinical medicine
|January 25, 2025
概括
高风险神经母细胞瘤,由MYCN放大驱动,显示免疫和糖化基因表达的改变. 一个12基因的糖化定位预测了患者的存活率,为这种侵袭性儿科癌症提供了新的见解.
科学领域:
- 儿科瘤学 儿科瘤学
- 癌症基因组学 癌症基因组学
- 免疫基因组学是什么
背景情况:
- 神经母细胞瘤是一种具有变化的结果的侵袭性儿科癌症.
- 高风险神经母细胞瘤由于对遗传驱动因素的了解不足,因此存在重大治疗挑战.
- 了解基因表达差异对于改善预后至关重要.
研究的目的:
- 研究神经母细胞瘤中的基因表达模式.
- 确定与不良预后相关的监管机制.
- 为神经母细胞瘤患者制定基于基因的风险概况.
主要方法:
- 在493个神经母细胞瘤瘤mRNA测序数据的分析 (GSE49711).
- 非假设驱动的再分析以确定预后基因表达模式.
- 全球基因表达与临床参数的整合.
主要成果:
- 分层神经母细胞瘤样本成两个不同的基因表达群.
- 确定MYCN放大是不良预后和特定基因调节的关键驱动因素.
- 由MYCN增强的瘤显示出免疫基因调节的改变,免疫透的减少,以及调节的糖系转移酶基因.
结论:
- 在神经母细胞瘤中,MYCN放大驱动了通过免疫反应和糖化基因调节的不良预后.
- 一个基于12基因糖化基因的风险概况与患者的生存结果准确相关.
- 这项研究为神经母细胞瘤预后提供了一种新的遗传标记.
更多相关视频
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.1K
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
1.5K
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenomics: Identification of New Drug Targets
91
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
91
